What Is Gonadorelin?
Gonadorelin is the pharmaceutical name for synthetic gonadotropin-releasing hormone, usually shortened to GnRH. It has the same ten-amino-acid sequence as the natural human hormone that links the brain with the reproductive system.
Unlike many compounds in this library, gonadorelin has an established medical history. Human products were approved in the United States for diagnostic testing and pulsatile fertility treatment, although those products were later discontinued from marketing. The timing of exposure is central to its effect, which is why isolated claims that it “raises testosterone” or “restores fertility” can be misleading.
What does gonadorelin do in the body?
The hypothalamus is a brain region that helps control temperature, appetite, stress and hormone systems. Specialised hypothalamic nerve cells release GnRH into a small blood-vessel network leading directly to the pituitary gland.
GnRH binds to receptors on pituitary cells. A receptor is a protein that receives a chemical signal. The pituitary then releases two gonadotropins:
- luteinising hormone, shortened to LH;
- follicle-stimulating hormone, shortened to FSH.
In people with ovaries, LH and FSH regulate follicle development, ovulation and the production of oestrogen and progesterone. A follicle is the ovarian structure containing a developing egg. In people with testes, LH stimulates testosterone production and FSH supports sperm production.
This linked system is called the hypothalamic-pituitary-gonadal axis. “Axis” means a connected hormone-control network, not a physical structure.
What is gonadorelin made from?
Gonadorelin is a decapeptide, meaning a chain of ten amino acids. Its sequence is:
`pyroglutamic acid-histidine-tryptophan-serine-tyrosine-glycine-leucine-arginine-proline-glycinamide`
The first amino acid forms a ring called pyroglutamic acid, and the final glycine is amidated. Amidation adds an amide group at the end of the peptide. These features are part of natural human GnRH and help define its activity.
Gonadorelin acetate and gonadorelin hydrochloride are salt forms used in pharmaceutical products. A salt form pairs the peptide with another ion to help with manufacture or formulation. It does not turn gonadorelin into a long-acting GnRH analogue.
When was GnRH first documented?
Researchers knew that the hypothalamus controlled pituitary reproductive hormones before they had isolated the signal. During the 1960s and early 1970s, teams led by Andrew Schally and Roger Guillemin purified hypothalamic material and identified the ten-amino-acid sequence of GnRH.
Both groups reported the structure around 1971. Their work helped establish the wider concept of hypothalamic releasing hormones. Guillemin and Schally shared the 1977 Nobel Prize in Physiology or Medicine with Rosalyn Yalow for discoveries concerning peptide hormones and radioimmunoassay.
Synthetic production made diagnostic and treatment studies possible. Factrel, a gonadorelin hydrochloride injection, was approved by the FDA in 1982 for diagnostic use. Lutrepulse, a gonadorelin acetate product used with a programmable pump, received US approval in 1989.
| Year | Development |
|---|---|
| 1960s | Hypothalamic control of pituitary gonadotropins was demonstrated experimentally |
| Around 1971 | The ten-amino-acid GnRH sequence was isolated and identified |
| 1977 | Schally and Guillemin shared the Nobel Prize for peptide-hormone discoveries |
| 1982 | FDA approved human gonadorelin hydrochloride as Factrel for diagnostic use |
| 1989 | FDA approved gonadorelin acetate as Lutrepulse |
| 1990s | Pulsatile treatment evidence was reported in hypothalamic amenorrhoea |
| Later years | US human Factrel and Lutrepulse products were discontinued from marketing |
How is gonadorelin synthesised and manufactured?
Gonadorelin can be made by solid-phase peptide synthesis. A protected amino acid is attached to a resin, and the remaining protected amino acids are added one at a time in the required sequence. Coupling reagents help form the peptide bonds.
The pyroglutamic acid at the beginning and amide at the end must be produced correctly. After assembly, the peptide is removed from the resin, protecting groups are cleared and the crude material is purified by liquid chromatography.
Mass spectrometry, peptide mapping and analytical chromatography help confirm sequence and purity. Raw materials include protected amino acids, resin, coupling reagents, solvents, acids and bases. Acetic acid or hydrochloric acid may be used to prepare the chosen salt form.
A finished injectable medicine requires sterile manufacture, endotoxin and particle testing, validated strength and stability. A pump-based medicine also requires compatibility between the peptide, reservoir, tubing and delivery device over the intended use period.
Why do pulses matter?
Natural GnRH is released in pulses rather than as a steady stream. The frequency and size of the pulses change across puberty, the menstrual cycle and different physiological states.
Intermittent receptor stimulation allows pituitary cells to respond with LH and FSH pulses. Continuous exposure can cause receptor desensitisation and down-regulation. Desensitisation means that a receptor system responds less after persistent stimulation. Down-regulation means that cells reduce the number or availability of receptors.
This explains why long-acting GnRH agonists can eventually suppress sex hormones even though they initially stimulate the same receptor. An agonist is a molecule that activates a receptor. Gonadorelin itself is short acting, while modified agonists such as leuprolide are designed to last longer.
It also explains why administration timing is not a minor detail. A claim about the molecule without its exposure pattern is incomplete.
What was the diagnostic use of Factrel?
Human Factrel contained gonadorelin hydrochloride. Clinicians used a single GnRH stimulation test to assess how the pituitary released LH and FSH. Blood was taken before and after administration.
The test could help distinguish hypothalamic problems, where the brain was not providing enough GnRH, from some pituitary problems, where the gland could not respond normally. Interpretation depended on age, sex, pubertal stage, baseline hormones and the clinical question.
Modern hormone testing and imaging have changed diagnostic practice. The historical approval does not mean an unapproved gonadorelin product should be used for self-testing.
What is hypothalamic amenorrhoea?
Amenorrhoea means the absence of menstrual periods. In hypothalamic amenorrhoea, the hypothalamus releases GnRH too slowly or irregularly to support normal LH and FSH pulses and ovulation.
Causes can include low energy availability, substantial exercise, stress, low body weight, chronic illness or congenital GnRH deficiency. Diagnosis requires assessment because pregnancy, polycystic ovary syndrome, high prolactin, thyroid disease and ovarian conditions can also alter periods.
Replacing the missing signal with pulsatile gonadorelin can reproduce part of normal physiology in carefully selected patients. It is not a general fertility treatment for every cause of infertility.
What did the 109-woman Lutrepulse study find?
The published analysis involved 109 women with primary or secondary hypothalamic amenorrhoea. Primary amenorrhoea means menstrual periods have never begun. Secondary amenorrhoea means previously present periods have stopped.
Participants received pulsatile intravenous gonadorelin through the Lutrepulse system. The study reported ovulation in 91% of women with primary hypothalamic amenorrhoea and 96% with secondary hypothalamic amenorrhoea.
The report recorded complications related to intravenous line placement, with an overall mean of 7% across centres. Multiple pregnancy occurred in 12%. One case of ovarian hyperstimulation was reported in a woman who also received clomiphene citrate, a fertility medicine that stimulates ovulation.
These results support the biological principle of replacing a deficient pulse signal. They do not show that gonadorelin is suitable for infertility caused by blocked fallopian tubes, impaired sperm, ovarian failure or every other reproductive condition.
Study design, not dosing guidance
The Lutrepulse system delivered small intravenous pulses at programmed intervals. Other studies examined subcutaneous pulses, meaning delivery into tissue beneath the skin. The exact pulse interval and amount were chosen to reproduce a physiological signal in diagnosed hypothalamic deficiency.
Those settings required hormone monitoring, ultrasound and fertility care. They are not instructions for unsupervised use, testosterone manipulation or post-cycle treatment.
What did the dose-comparison study find?
A controlled study involved 18 women with well-characterised hypothalamic amenorrhoea across 30 treatment cycles. Researchers compared two pulsatile GnRH exposure levels.
Both could produce ovulation and fertility, but the lower level appeared near the threshold for pituitary-ovarian stimulation and was associated with an inadequate luteal phase in some cycles. The luteal phase is the part of the menstrual cycle after ovulation, when progesterone supports the uterine lining. The higher level could produce stimulation above the normal physiological range.
The study shows why “more” is not a neutral adjustment. Hormone systems depend on timing and magnitude, and both insufficient and excessive stimulation can alter the outcome.
Has gonadorelin been studied in men?
Pulsatile GnRH has been used in specialist care for men with hypogonadotropic hypogonadism. Hypogonadism means inadequate function of the testes or ovaries. Hypogonadotropic means the problem is associated with insufficient LH and FSH stimulation.
In a person whose pituitary and testes can respond, restoring pulses may increase LH, FSH, testosterone and sperm production. This is replacement of a missing hypothalamic signal, not a general testosterone-enhancement method.
The response can take months because sperm development is slow. Congenital conditions, prior puberty, testicular function and other pituitary hormones affect results. Specialist monitoring is necessary.
Does gonadorelin raise testosterone in healthy men?
A GnRH pulse can cause a temporary LH response, followed by testosterone production if the pituitary and testes respond. That physiological fact does not establish a safe or useful performance treatment.
Repeated exposure with the wrong pattern may reduce responsiveness. Elevated testosterone can also affect fertility, red blood-cell production, prostate symptoms and other systems. Gonadorelin is not an approved bodybuilding or routine “testosterone optimisation” treatment.
Does gonadorelin preserve fertility during testosterone treatment?
External testosterone can suppress hypothalamic GnRH, pituitary LH and FSH, and sperm production. Online clinics sometimes claim that gonadorelin can replace human chorionic gonadotropin, or hCG, during testosterone treatment.
hCG acts directly on the LH receptor in the testes. Gonadorelin acts upstream at the pituitary and depends on pulsatile exposure and pituitary responsiveness. They are not interchangeable molecules.
There is no strong evidence that an occasional gonadorelin injection reliably preserves fertility during external testosterone treatment. Fertility goals require semen analysis and specialist management, not assumptions based on a brief hormone response.
How does gonadorelin differ from long-acting GnRH agonists?
Gonadorelin is identical to natural GnRH and is broken down quickly. Leuprolide, goserelin and nafarelin are modified analogues that last longer. Continuous action initially stimulates and then suppresses the pituitary-gonadal axis.
Long-acting agonists are used in conditions such as prostate cancer, endometriosis and central precocious puberty. Their evidence and approved labels do not apply to gonadorelin.
GnRH antagonists are another class. An antagonist blocks a receptor rather than activating it. These medicines can suppress LH and FSH without the initial stimulation associated with an agonist.
What are the safety concerns?
Adverse effects depend on the use, route and exposure pattern. Diagnostic administration can cause headache, flushing, nausea, light-headedness or local reactions. Allergic reactions are possible.
Pulsatile fertility treatment can cause ovarian enlargement, multiple pregnancy and, less commonly, ovarian hyperstimulation. Ovarian hyperstimulation syndrome involves enlarged ovaries and fluid shifts and can become serious. Pump and intravenous-line use add risks of infection, inflammation, blockage and delivery failure.
In people with hormone-sensitive conditions, stimulating reproductive hormones may be inappropriate. Pregnancy, unexplained bleeding, pituitary tumours and several endocrine disorders require medical assessment.
An unapproved product adds risks of incorrect identity, contamination, endotoxin, unstable formulation and inaccurate strength. A natural sequence does not eliminate those risks.
Is gonadorelin approved and available?
The United States previously approved human gonadorelin products. Factrel received approval in 1982 for diagnostic use. Lutrepulse received approval in 1989 and an orphan approval record for ovulation induction in women with hypothalamic amenorrhoea due to deficient GnRH secretion.
The human products were discontinued from US marketing. A discontinued product is not necessarily withdrawn for safety reasons, but it is not currently available as an ordinary marketed human medicine.
DailyMed now contains a veterinary Factrel label for gonadorelin hydrochloride used in cattle. DailyMed is the US National Library of Medicine's label database. The reused brand name can cause confusion: the veterinary product is not the discontinued human Factrel medicine and is not for human use.
Availability and approval differ between countries. A compounded gonadorelin preparation is not the same as the former approved finished product.
What benefits are claimed, and what does the evidence support?
| Claim | What the evidence supports |
|---|---|
| Restores ovulation | Established for selected women with deficient hypothalamic GnRH when delivered in physiological pulses |
| Treats all infertility | Not supported; benefit depends on the cause |
| Raises testosterone | Can restore signalling in diagnosed GnRH deficiency; not a general enhancement treatment |
| Preserves fertility during external testosterone | No strong evidence for occasional unapproved use |
| Replaces hCG | Not equivalent; the medicines act at different points |
| Is the same as long-acting GnRH agonists | No; structure, duration and exposure pattern differ |
| Current Factrel is a human medicine | No; the current US label under that name is veterinary |
What monitoring was used in medical treatment?
Specialist fertility programmes monitored LH, FSH, oestradiol, progesterone, follicle development and ovulation. Ultrasound can measure ovarian follicles. Pregnancy monitoring matters because multiple pregnancy is a recognised risk.
In men, programmes may monitor LH, FSH, testosterone, testicular development and semen analysis. These measurements help determine whether the pituitary and gonads are responding.
This monitoring is part of why older medical evidence cannot be reduced to an exposure number.
How did the GnRH stimulation test work?
Clinicians measured baseline LH and FSH, administered a defined human gonadorelin product and collected further blood samples. The size and timing of the hormone rise showed whether the pituitary could respond.
A normal response did not identify every possible cause of reproductive symptoms. A weak response could reflect age, pubertal stage, prolonged lack of natural stimulation, pituitary disease or test conditions. Results had to be interpreted with the person's history and other hormone tests.
Modern ultrasensitive hormone assays, genetic tests and magnetic resonance imaging can answer questions that were harder to resolve when Factrel was introduced. Diagnostic practice therefore changed even though the underlying physiology remains valid.
What is congenital GnRH deficiency?
Some people are born with impaired development or function of GnRH-producing nerve cells. This can cause absent or incomplete puberty and infertility. When it occurs with a reduced or absent sense of smell, it may be called Kallmann syndrome.
The pituitary and gonads may still be able to respond if supplied with the missing signal. Pulsatile GnRH can therefore be physiologically appropriate in selected cases. Other people need direct gonadotropin treatment because a pump is unavailable or the response differs.
Congenital deficiency is not the same as temporary suppression from low energy availability, illness or external hormones. Diagnosis changes the treatment question.
How does pulsatile gonadorelin compare with gonadotropins?
Gonadotropin medicines provide FSH, LH activity or both directly. Gonadorelin asks the pituitary to release the body's own gonadotropins. It only works if the pituitary can respond.
Pulsatile GnRH can promote development of a single leading ovarian follicle in a pattern closer to physiology. Direct gonadotropins can stimulate more than one follicle, which may increase multiple-pregnancy and ovarian-hyperstimulation risk.
Neither approach is risk free. Pumps and intravenous lines can fail or become infected, and pregnancy monitoring remains necessary. Choice depends on diagnosis, product availability and specialist experience.
Why is a single hormone reading insufficient?
LH and testosterone are released in pulses and change across the day. In menstruating people, LH, FSH, oestradiol and progesterone vary across the cycle. A single result may not represent the usual pattern.
Illness, undernutrition, sleep loss, medicines and recent exercise can also affect the axis. Clinicians interpret repeated morning measurements or cycle-timed tests where appropriate.
An immediate hormone rise after gonadorelin shows short-term responsiveness. It does not prove sustained fertility, sperm production or a safe long-term treatment effect.
Why can continuous GnRH suppress fertility?
Persistent receptor activation causes pituitary cells to reduce signalling and receptor availability. LH and FSH initially rise, a response called a flare, then fall with continued long-acting stimulation.
This property is used deliberately by long-acting GnRH agonist medicines. Lower sex-hormone production can help treat prostate cancer, endometriosis and central precocious puberty. Those uses involve modified molecules and regulated formulations.
The contrast shows why molecule, formulation and time pattern must be described together. Saying that a substance “stimulates GnRH receptors” does not predict the final hormone effect.
What does discontinuation of a medicine mean?
A manufacturer can stop marketing a product for commercial, manufacturing or clinical reasons. Discontinuation is not automatically a safety withdrawal. The FDA's discontinued-products records distinguish products that are no longer sold from those withdrawn because of safety or effectiveness concerns.
The former approval remains part of medical history, but it does not make a newly compounded preparation the same product. The manufacturer, inactive ingredients, delivery system and quality controls may all differ.
For Lutrepulse, the pump and its programmed pulses were part of the treatment system. Possessing gonadorelin without the validated delivery system does not reproduce the approved evidence.
What would evidence for a new gonadorelin product require?
A modern product would need to demonstrate sequence identity, purity, sterility and stability. If delivered by a pump, dose accuracy, reservoir stability, alarms and tubing compatibility would also need validation.
Clinical development would depend on the proposed use. A diagnostic product would need to show that its test result helps classify patients accurately. A fertility product would measure ovulation, pregnancy, live birth, multiple pregnancy and adverse events.
Claims involving men using external testosterone would require controlled research measuring sperm concentration, total sperm count, hormones and pregnancy outcomes. A brief LH response would not be enough.
What outcomes matter in female fertility research?
Ovulation is an important biological outcome but is not the final goal for someone trying to have a child. Trials can also report time to pregnancy, clinical pregnancy confirmed by ultrasound, live birth, miscarriage and multiple pregnancy.
Follicle development and hormone levels help clinicians understand the response. They are intermediate outcomes. A high ovulation rate can coexist with lower pregnancy or live-birth rates if other fertility factors are present.
The 109-woman Lutrepulse analysis showed high ovulation rates in the selected diagnosis. It also reported multiple pregnancies and line complications, which belong in the benefit-risk assessment.
What outcomes matter in male fertility research?
Semen analysis measures volume, sperm concentration, total count, movement and shape. Results vary between samples, so repeat testing is common. A higher testosterone result does not prove that sperm production has recovered.
Pulsatile GnRH may take months to support testicular growth and spermatogenesis, the process of making sperm. Pregnancy outcomes also depend on the fertility of both partners.
Trials should report who had congenital deficiency, prior puberty and previous treatment because these factors can affect response.
Why can unapproved clinic use differ from the historical evidence?
Historical fertility treatment used frequent programmed pulses to reproduce physiology. Some modern clinic protocols use occasional injections after testosterone treatment. Those exposure patterns are not equivalent.
External testosterone suppresses the hypothalamus and pituitary. If the pituitary has been persistently suppressed, a single gonadorelin exposure may produce a different response from pulses used in untreated congenital deficiency.
Evidence should therefore match the exact clinical situation. A paper in women with hypothalamic amenorrhoea cannot validate a male hormone-clinic protocol.
What are the implications for people with eating or exercise-related amenorrhoea?
Functional hypothalamic amenorrhoea can result from insufficient energy availability, stress or intensive exercise. Low oestrogen may affect bone health, and the underlying energy deficit can affect many organs.
Restoring a hormone signal can induce ovulation, but it does not correct undernutrition or the wider cause. Care may involve nutrition, changes in training, psychological support and assessment of bone health.
This is another reason gonadorelin is not a simple fertility switch. A physiological response and recovery of overall health are related but separate outcomes.
Frequently asked questions
Is gonadorelin a peptide?
Yes. It is a ten-amino-acid peptide identical in sequence to human GnRH.
Is gonadorelin the same as GnRH?
Gonadorelin is the pharmaceutical name for synthetic GnRH.
What hormones does gonadorelin release?
It stimulates the pituitary to release luteinising hormone and follicle-stimulating hormone.
Does gonadorelin increase testosterone?
It can restore testosterone production in selected people with deficient GnRH signalling and responsive pituitary and testes. This is not evidence for general enhancement.
Was gonadorelin FDA approved?
Yes, human Factrel and Lutrepulse products received US approvals. Those human products were later discontinued from marketing.
Is current Factrel for people?
The current US DailyMed Factrel label is a veterinary product for cattle. It should not be confused with the discontinued human medicine.
Why must gonadorelin be pulsatile for fertility treatment?
Natural GnRH signals arrive in pulses. Persistent stimulation can make the pituitary less responsive.
Is gonadorelin the same as hCG?
No. Gonadorelin acts on the pituitary GnRH receptor. hCG acts mainly on LH receptors in the gonads.
Sources
Research reviewed through September 2026.